Anavex Life Sciences is back with more data for a pill that it’s looking to get approved in a variety of neurodegenerative ...
For as long as I’ve been a healthcare reporter, the JP Morgan Healthcare Conference has served as a newsy way … Get ...
Daiichi Sankyo is spending $132.5 million to buy an antibody outright that it had already licensed from Glycotope.
IgA1 reduction in 4 hours, outperforming Vertex's povetacicept and Otsuka's sibeprenlimab. Plans for Phase 3 in IgAN.
IgA1 reduction in 4 hours, outperforming Vertex's povetacicept and Otsuka's sibeprenlimab. Plans for Phase 3 in IgAN.
XO Health launches health plan in 4 cities, offering employers alternative coverage with fixed-price care packages and ...
Moderna is slashing its 2025 revenue estimate by $1 billion and expanding cost-cutting measures as it continues to struggle ...
The US Court of Appeals for the Federal Circuit on Friday found a key patent of Novartis' Entresto valid, reversing a lower ...
Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...
Health tech sees strong start to 2025 with five $100M+ funding rounds, including Evergreen Nephrology, Qventus, ...
Former FDA Commissioner Scott Gottlieb said Robert F. Kennedy Jr. should not lead the US health agencies, underscoring the risk of further eroding faith in vaccines.
AbbVie partners with Simcere Zaiming in up to $1.1B deal to develop SIM0500 for multiple myeloma; drug currently in Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback